Cellares and ProTgen Automate Manufacturing of Progenitor T-Cell Therapy for Blood Cancer
The partnership will automate manufacturing and quality control of ProT-096, ProTgen’s personalized progenitor T-cell therapy for refractory leukemia and other hematologic malignancies. Cellares will also provide regulatory support toward IND submission. The post Cellares and ProTgen Automate Manufacturing of Progenitor T-Cell Therapy for Blood Cancer appeared first on GEN - Genetic Engineering and Biotechnology News.
Original Source
Read the full article at Genengnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.